| Tavegil (clemastine) / GSK |
| Completed | 2 | 49 | Europe | Omalizumab 75-375 mg, Xolair, Placebo to omalizumab, Loratadine, Lorano®, Clemastine, Tavegil® | Novartis | Chronic Urticaria | 04/09 | 04/09 | | |
| Completed | 2 | 50 | US | Clemastine, Clemastine Fumarate,, Tavist -1, Placebo | University of California, San Francisco | Multiple Sclerosis, Relapsing-Remitting | 09/15 | 04/16 | | |
2018-001756-35: A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis |
|
|
| Not yet recruiting | 2 | 70 | Europe | TAVEGIL TABLETS, Tablet, TAVEGIL TABLETS | University of California, San Francisco | acute optic neuritis, Optic neuritis is an inflammatory, demyelinating disease of the optic nerve. It is most often characterized by visual loss or blurred vision along with dyschromotopsia accompanied by pain., Body processes [G] - Cell Physiological Phenomena [G04] | | | | |
2022-000054-28: Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat) Die Behandlung der kognitiven Dysfunktion durch Verbesserung der Myelinplastizität mittels Kombination von Clemastin und aerobem Ausdauertraining bei Patienten mit einer Schizophrenie (OligoTreat) |
|
|
| Not yet recruiting | 2 | 90 | Europe | Clemastinfumarat, Tablet | Klinikum der Universität München, Stanley Foundation | Schizophrenia Schizophrenie, Schizophrenia Schizophrenie, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT05131828: CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy |
|
|
| Recruiting | 2 | 70 | Europe | Metformin and clemastine in combination, Placebo | Cambridge University Hospitals NHS Foundation Trust, University of Cambridge | Multiple Sclerosis | 05/25 | 05/25 | | |
OligoTreat, NCT06315972: Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity |
|
|
| Not yet recruiting | 2 | 90 | NA | clemastine (8 mg/day), Placebo | LMU Klinikum | Schizophrenia | 11/26 | 04/28 | | |
| Recruiting | 2 | 90 | US | Clemastine, Tavist, Clemastine fumarate, Walhist, Placebo | University of California, San Francisco, Moorfields Eye Hospital NHS Foundation Trust | Optic Neuritis | 08/26 | 08/26 | | |
NCT03109288: Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) |
|
|
| Recruiting | 1/2 | 250 | US | Pioglitazone, clemastine fumarate, Dantrolene, Pirfenidone | National Institute of Allergy and Infectious Diseases (NIAID) | Multiple Sclerosis | 01/25 | 01/29 | | |
ReVIVE, NCT05359653: Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy |
|
|
| Recruiting | 1/2 | 74 | US | Clemastine Fumarate, Clemastine, Dayhist, Dayhist Allergy, Placebo, Sugar pill | University of California, San Francisco, United States Department of Defense | Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis Relapse, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Benign | 06/25 | 06/25 | | |
ReINFORCE, NCT06065670: Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy |
|
|
| Not yet recruiting | 1/2 | 44 | US | Clemastine Fumarate, Clemastine, Dayhist, Dayhist Allergy, Placebo, Sugar pill | University of California, San Francisco | Demyelinating Diseases, Demyelination; Corpus Callosum, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Acute and Progressive, Clinically Isolated Syndrome, CNS Demyelinating | 10/26 | 10/26 | | |
